Sevoflurane In Acute Myocardial Infarction (SIAMI)

Lawson Health Research Institute

Status and phase: Completed; Phase 2

Conditions: Acute Myocardial Infarction

Treatments: Drug: Oxygen (placebo); Drug: Oxygen + Sevoflurane

Study type: Interventional

Funder types: Other

Identifiers

NCT00971607

R-09-165

15793 (Other Identifier)

Details and patient eligibility

About

Ischemic postconditioning can reduce myocardial injury following myocardial infarction.

A potential pharmacological agent is the anesthetic Sevoflurane. The investigators' hypothesis is that sevoflurane during primary percutaneous coronary intervention (PCI) will reduce infarct size.

Full description

Patients with first STEMI that will be treated by primary PCI, will be randomized to sedation with Sevoflurane during the procedure or to usual care.

Enrollment: 50 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• First STEMI, presenting within 6 hours after the onset of chest pain
• Symptoms lasting > 30 minutes
• Persistent ST-segment elevation > 0.1 mV in 2 or more contiguous leads

Exclusion criteria

• Hypersensitivity to sevoflurane or other halogenated agents
• Malignant hyperthermia
• Cardiac arrest
• Cardiogenic shock
• Previous myocardial infarction or coronary bypass surgery
• Pre-infarction angina
• Heart failure (NYHA III/IV)
• Chronic inflammatory disease
• Severe renal impairment
• Hepatic dysfunction
• Use of Glyburide

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

50 participants in 2 patient groups, including a placebo group

1

Active Comparator group

Description:

Sevoflurane

Treatment:

Drug: Oxygen + Sevoflurane

2

Placebo Comparator group

Description:

Oxygen

Treatment:

Drug: Oxygen (placebo)